Related Experiment Video

Updated: Apr 9, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

11.8K

Repurposing an Osteoporosis Drug for β Cell Regeneration in Diabetic Patients

Felizitas Schmitz1, Sara Roscioni1, Heiko Lickert2

  • 1Institute of Diabetes and Regeneration Research, Helmholtz Center Munich, Am Parkring 11, 85748 Garching, Germany.

Cell Metabolism
|June 23, 2015
PubMed

Insights

Osteoprotegerin and denosumab, inhibitors of the receptor activator of the NF-κB Ligand (RANKL) pathway, promote human beta cell proliferation. This finding suggests a potential new therapeutic strategy for diabetes by regenerating insulin-producing cells.

Area of Science:

  • Endocrinology and Metabolism
  • Cell Biology
  • Pharmacology

Background:

  • Diabetes mellitus is characterized by loss or dysfunction of insulin-producing beta cells.
  • Regenerating beta cell mass is a key therapeutic goal for diabetes treatment.

Purpose of the Study:

  • To investigate the potential of osteoprotegerin and denosumab in stimulating human beta cell proliferation.
  • To explore the therapeutic implications of targeting the RANKL pathway for diabetes.

Main Methods:

  • Utilized osteoprotegerin and denosumab, known inhibitors of the receptor activator of the NF-κB Ligand (RANKL) pathway.
  • Assessed the effect of these inhibitors on human beta cell proliferation in vitro.

Main Results:

  • Osteoprotegerin and denosumab significantly stimulated the proliferation of human beta cells.
  • Inhibition of the RANKL pathway demonstrated a positive effect on beta cell regeneration.

Conclusions:

  • Osteoprotegerin and denosumab exhibit therapeutic potential for diabetes by enhancing beta cell proliferation.
  • Targeting the RANKL pathway represents a promising avenue for developing novel diabetes therapies.

More Related Videos

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.8K
In Vitro Colony Assays for Characterizing Tri-potent Progenitor Cells Isolated from the Adult Murine Pancreas09:31

In Vitro Colony Assays for Characterizing Tri-potent Progenitor Cells Isolated from the Adult Murine Pancreas

Published on: June 10, 2016

9.9K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Tissue Renewal without Stem Cells01:23

Tissue Renewal without Stem Cells

After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...
2.3K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.0K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
977
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
974
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
8.7K